Bimekizumab shows therapeutic potential in certain RA patients
Dual neutralization with interleukin (IL)-7A and IL-17F with bimekizumab produces rapid reductions in disease activity in rheumatoid arthritis (RA) patients with inadequate response to certolizumab pegol (CZP), as shown in the results of a phase IIa, proof-of-concept study.
A total of 159 adult patients with moderate-to-severe RA had received open-label CZP 400 mg at weeks 0, 2 and 4, and 200 mg at week 6. Of these, 79 patients showed inadequate response (Disease Activity Score 28-joint count C-reactive protein [DAS28(CRP)] >3.2) to CZP at week 8.
The 79 patients were then randomly assigned to treatment with CZP 200 mg every 2 weeks (Q2W) plus bimekizumab 240 mg loading dose then 120 mg Q2W (n=52; median age, 53 years; 86.5 percent female) or CZP plus placebo (n=27; median age, 57 years; 85.2 percent female).
DAS28(CRP) at week 20 from week 8, the primary efficacy endpoint, decreased significantly in the bimekizumab vs placebo arm (mean change, –1.41 vs –0.82; 99.4 percent posterior probability).
The most frequent treatment-emergent adverse events were infections and infestations, occurring in 50.0 percent of patients in the bimekizumab arm and in 22.2 percent in the placebo arm.
The present data indicate that bimekizumab has therapeutic potential in RA patients with inadequate response to CZP, supporting further exploration of concomitant neutralization of multiple pathways in other patient populations where this treatment strategy may provide additional benefits, according to researchers.